U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C6H5O7.3Zn
Molecular Weight 574.3866
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZINC CITRATE

SMILES

C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[ZnH2+2].[ZnH2+2].[ZnH2+2]

InChI

InChIKey=WGIWBXUNRXCYRA-UHFFFAOYSA-H
InChI=1S/2C6H8O7.3Zn/c2*7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h2*13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;;3*+2/p-6

HIDE SMILES / InChI

Molecular Formula Zn
Molecular Weight 65.3956
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C6H5O7
Molecular Weight 189.1
Charge -3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Zinc oxide is an inorganic compound with the formula ZnO. ZnO is a white powder that is insoluble in water, and it is widely used as an additive in numerous materials and products including rubbers, plastics, ceramics, glass, cement, lubricants, paints, ointments, adhesives, sealants, pigments, foods, batteries, ferrites, fire retardants, and first-aid tapes. Although it occurs naturally as the mineral zincite, most zinc oxide is produced synthetically. Zinc oxide is widely used to treat a variety of skin conditions, including dermatitis, itching due to eczema, diaper rash and acne. It is used in products such as baby powder and barrier creams to treat diaper rashes, calamine cream, anti-dandruff shampoos, and antiseptic ointments. It is also a component in tape (called "zinc oxide tape") used by athletes as a bandage to prevent soft tissue damage during workouts. Zinc oxide can be used in ointments, creams, and lotions to protect against sunburn and other damage to the skin caused by ultraviolet light (see sunscreen). It is the broadest spectrum UVA and UVB absorber that is approved for use as a sunscreen by the U.S. Food and Drug Administration (FDA), and is completely photostable. When used as an ingredient in sunscreen, zinc oxide blocks both UVA (320–400 nm) and UVB (280–320 nm) rays of ultraviolet light. Zinc oxide and the other most common physical sunscreen, titanium dioxide, are considered to be nonirritating, nonallergenic, and non-comedogenic. Zinc oxide nanoparticles can enhance the antibacterial activity of ciprofloxacin. It has been shown that nano ZnO which has the average size between 20 nm and 45 nm can enhance the antibacterial activity of ciprofloxacin against Staphylococcus aureus and Escherichia coli in vitro. The enhancing effect of this nanomaterial is concentration dependent against all test strains. This effect may be due to two reasons. First, zinc oxide nanoparticles can interfere with NorA protein, which is developed for conferring resistance in bacteria and has pumping activity that mediate the effluxing of hydrophilic fluoroquinolones from a cell. Second, zinc oxide nanoparticles can interfere with Omf protein, which is responsible for the permeation of quinolones into the cell.

Originator

Curator's Comment:: The use of pushpanjan, probably zinc oxide, as a salve for eyes and open wounds, is mentioned in the Indian medical text the Charaka Samhita, thought to date from 500 BC or before. Zinc oxide ointment is also mentioned by the Greek physician Dioscorides (1st century AD.)

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: ultraviolet B-induced damage
Target ID: Q9NY26
Gene ID: 27173.0
Gene Symbol: SLC39A1
Target Organism: Homo sapiens (Human)
Target ID: Q9NP94
Gene ID: 29986.0
Gene Symbol: SLC39A2
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Unknown

Approved Use

Unknown
Primary
CORTROPHIN-ZINC

Approved Use

Treatment of ulcerative colitis and other colonic disorders.

Launch Date

-4.55328006E11
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Secondary
VORAXAZE

Approved Use

Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate.

Launch Date

1.32675836E12
Primary
VUSION

Approved Use

INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes.

Launch Date

1.140048E12
Primary
ZINC OXIDE

Approved Use

Unknown
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
PubMed

PubMed

TitleDatePubMed
In vitro activity of zinc salts against human rhinoviruses.
1987 Apr
A medicated polycarboxylate cement to prevent complications in composite resin therapy.
1990 Jan
Molecular modeling studies suggest that zinc ions inhibit HIV-1 protease by binding at catalytic aspartates.
1993 Aug
Cupric ion blocks NF kappa B activation through inhibiting the signal-induced phosphorylation of I kappa B alpha.
1995 Nov 13
SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus.
1997 Feb
Thujaplicin-copper chelates inhibit replication of human influenza viruses.
1998 Aug
Effects of trace metal compounds on HIV-1 reverse transcriptase: an in vitro study.
1999 May
Inhibition of HIV-1 infection by zinc group metal compounds.
1999 Sep
Combined effects of argon laser irradiation and fluoride treatments in prevention of caries-like lesion formation in enamel: an in vitro study.
1999 Spring
Comparison of the levels of copper, zinc and iron in cervical mucus and in blood serum of women of childbearing age.
2004
Inhibition by copper(II) binding of hepatocyte growth factor (HGF) interaction with its receptor Met and blockade of HGF/Met function.
2004 Jul 30
Erythrocyte zinc content in critically ill patients.
2005
Zinc-induced anti-apoptotic effects in SH-SY5Y neuroblastoma cells via the extracellular signal-regulated kinase 1/2.
2005 Apr 27
Copper, zinc, and Cu/Zn ratio in carcinoma of the gallbladder.
2005 Sep 1
Effects of zinc supplementation in patients with type 1 diabetes.
2005 Summer
Characterization and inhibition of SARS-coronavirus main protease.
2006
Copper and zinc concentrations in serum of healthy Greek adults.
2006 Apr 15
Influence of dietary zinc and copper on digestive enzyme activity and intestinal morphology in weaned pigs.
2006 Dec
On the mechanism of the conversion of methanol to 2,2,3-trimethylbutane (triptane) over zinc iodide.
2006 Nov 10
Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
2007 Nov
Difficulty measuring methotrexate in a patient with high-dose methotrexate-induced nephrotoxicity.
2010 Dec
In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles.
2010 Dec 1
Role of the dissolved zinc ion and reactive oxygen species in cytotoxicity of ZnO nanoparticles.
2010 Dec 15
Oxidative stress, calcium homeostasis, and altered gene expression in human lung epithelial cells exposed to ZnO nanoparticles.
2010 Feb
Glucarpidase following high-dose methotrexate: update on development.
2010 Jan
Engineered nanomaterials cause cytotoxicity and activation on mouse antigen presenting cells.
2010 Jan 12
Glucarpidase rescue in a patient with high-dose methotrexate-induced nephrotoxicity.
2011 Jun
High-dose methotrexate-induced renal dysfunction: is glucarpidase necessary for rescue?
2011 Mar 1
Titanium oxide shell coatings decrease the cytotoxicity of ZnO nanoparticles.
2011 Mar 21
Safety evaluation of sunscreen formulations containing titanium dioxide and zinc oxide nanoparticles in UVB sunburned skin: an in vitro and in vivo study.
2011 Sep
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles.
2012 Apr
Zinc oxide nanoparticles-induced intercellular adhesion molecule 1 expression requires Rac1/Cdc42, mixed lineage kinase 3, and c-Jun N-terminal kinase activation in endothelial cells.
2012 Mar
Molecular cloning, characterization of copper/zinc superoxide dismutase and expression analysis of stress-responsive genes from Eisenia fetida against dietary zinc oxide.
2012 Mar
Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry.
2013 Jan
TiO2, CeO2 and ZnO nanoparticles and modulation of the degranulation process in human neutrophils.
2013 Jul 31
Reactive oxygen species-induced cytotoxic effects of zinc oxide nanoparticles in rat retinal ganglion cells.
2013 Mar
Inorganic salts in atmospheric particulate matter: Raman spectroscopy as an analytical tool.
2013 Nov
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties.
2013 Nov 25
Zinc oxide nanoparticles induce migration and adhesion of monocytes to endothelial cells and accelerate foam cell formation.
2014 Jul 1
Additive effect of zinc oxide nanoparticles and isoorientin on apoptosis in human hepatoma cell line.
2014 Mar 3
Immunomodulatory activity of zinc peroxide (ZnO₂) and titanium dioxide (TiO₂) nanoparticles and their effects on DNA and protein integrity.
2014 May 16
Ultrasonic assisted removal of sunset yellow from aqueous solution by zinc hydroxide nanoparticle loaded activated carbon: Optimized experimental design.
2015
Synthesis aspects, structural, spectroscopic, antimicrobial and room temperature ferromagnetism of zinc iodide complex with Schiff based ligand.
2015 Jan 25
Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients.
2015 Sep
Simultaneous sulfate and zinc removal from acid wastewater using an acidophilic and autotrophic biocathode.
2016 Mar 5
Risk Assessment Study of Fluoride Salts: Probability-Impact Matrix of Renal and Hepatic Toxicity Markers.
2016 Sep
Intense 2.7μm emission in Er(3+) doped zinc fluoride glass.
2017 May 15
Patents

Sample Use Guides

Recommended Dietary Allowance (RDA)-expressed as elemental zinc: 19 years and older: Male: 11 mg (Upper intake limit: 34 mg); Female: 9 mg (Upper intake limit: 34 mg); Pregnancy: 11 mg (Upper intake limit: 40 mg); Lactation: 12 mg (Upper intake limit: 40 mg) Zinc sulfate injection: IV: Metabolically stable adults receiving TPN: 2.5 to 4 mg zinc/day Acute catabolic states on TPN: Additional 2 mg zinc per day is recommended. Stable adult with fluid loss from the small bowel: Additional 12.2 mg zinc/liter of small bowel fluid lost, or an additional 17.1 mg zinc/kg of stool or ileostomy output is recommended.
Route of Administration: Other
HeLa, COS-7, and HEK293-T cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Invitrogen) supplemented with 10% fetal calf serum (FCS, Invitrogen), glutamine (2 mM), penicillin (100 units/mL), and streptomycin (100 μg/mL). Two days before imaging, the cells were passed and plated on untreated (HeLa, COS-7) 10-mm glass coverslips or on glass coverslips coated with 0.2% gelatin for at least 1 h at room temperature (HEK293-T). For labeling, the growth medium was removed and replaced with DMEM containing 1% FCS. The cells were treated and incubated with 10 μM sensor at 37 °C under 5% CO2 for 30 min. The cells were washed once with and bathed in DMEM containing no FCS prior to imaging and/or zinc addition. Zinc was introduced to the cultured cells as the pyrithione salt using a Zn (II)/pyrithione ratio of 1:1 or 1:2. Stock solutions of ZnCl2 (10 mM) and sodium pyrithione (20 mM) in DMSO were combined and diluted 10-fold with DMEM prior to addition. In a typical experiment, a 100-μL aliquot of this solution was added to the cells bathed in 2 mL of DMEM. A stock solution of TPEN (10 or 20 mM) was also diluted 10-fold with DMEM containing no FCS prior to cell treatment.
Substance Class Chemical
Created
by admin
on Sat Jun 26 00:57:19 UTC 2021
Edited
by admin
on Sat Jun 26 00:57:19 UTC 2021
Record UNII
K72I3DEX9B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZINC CITRATE
INCI   MART.   MI   WHO-DD  
INCI  
Official Name English
CITRATED ZINC [VANDF]
Common Name English
2-HYDROXY-1,2,3-PROPANETRICARBOXYLIC ACID ZINC SALT
Common Name English
ZINC CITRATE [INCI]
Common Name English
ZINC CITRATE [MART.]
Common Name English
ZINC CITRATE [MI]
Common Name English
ZINC CITRATE [WHO-DD]
Common Name English
CITRATED ZINC
VANDF  
Common Name English
Classification Tree Code System Code
DSLD 137 (Number of products:9660)
Created by admin on Sat Jun 26 00:57:19 UTC 2021 , Edited by admin on Sat Jun 26 00:57:19 UTC 2021
Code System Code Type Description
ECHA (EC/EINECS)
208-901-2
Created by admin on Sat Jun 26 00:57:19 UTC 2021 , Edited by admin on Sat Jun 26 00:57:19 UTC 2021
PRIMARY
DRUG BANK
DB11154
Created by admin on Sat Jun 26 00:57:19 UTC 2021 , Edited by admin on Sat Jun 26 00:57:19 UTC 2021
PRIMARY
EVMPD
SUB15754MIG
Created by admin on Sat Jun 26 00:57:19 UTC 2021 , Edited by admin on Sat Jun 26 00:57:19 UTC 2021
PRIMARY
NCI_THESAURUS
C84247
Created by admin on Sat Jun 26 00:57:20 UTC 2021 , Edited by admin on Sat Jun 26 00:57:20 UTC 2021
PRIMARY
NCI_THESAURUS
C1505
Created by admin on Sat Jun 26 00:57:20 UTC 2021 , Edited by admin on Sat Jun 26 00:57:20 UTC 2021
CONCEPT Dietary Supplement
RXCUI
236911
Created by admin on Sat Jun 26 00:57:20 UTC 2021 , Edited by admin on Sat Jun 26 00:57:20 UTC 2021
PRIMARY RxNorm
MERCK INDEX
M11603
Created by admin on Sat Jun 26 00:57:20 UTC 2021 , Edited by admin on Sat Jun 26 00:57:20 UTC 2021
PRIMARY Merck Index
PUBCHEM
11023
Created by admin on Sat Jun 26 00:57:20 UTC 2021 , Edited by admin on Sat Jun 26 00:57:20 UTC 2021
PRIMARY
FDA UNII
K72I3DEX9B
Created by admin on Sat Jun 26 00:57:19 UTC 2021 , Edited by admin on Sat Jun 26 00:57:19 UTC 2021
PRIMARY
CAS
546-46-3
Created by admin on Sat Jun 26 00:57:19 UTC 2021 , Edited by admin on Sat Jun 26 00:57:19 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY